Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
About us
Our vision at Immunocore is to continue to deliver transformational science that transforms lives.
Our technology
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
Pipeline
We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Latest news
16 May 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
13 May 2019
Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer
7 May 2019
Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer
3 April 2019
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma